- Home
- FENC
as 04-18-2025 1:36pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 156.9M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 87.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $10.07 | Next Earning Date: | 05-13-2025 |
| Revenue: | $47,538,000 | Revenue Growth: | 123.69% |
| Revenue Growth (this year): | 2.68% | Revenue Growth (next year): | 71.63% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | FENC | Director | Apr 11 '25 | Sell | $4.95 | 1,409 | $6,974.55 | 53,784 | |
| Raykov Rosty | FENC | Director | Apr 4 '25 | Sell | $5.25 | 10,000 | $52,500.00 | 61,156 | |
| Raykov Rosty | FENC | Director | Mar 5 '25 | Sell | $6.79 | 10,000 | $67,900.00 | 61,156 | |
| RALLIS CHRIS A | FENC | Director | Feb 14 '25 | Sell | $6.82 | 1,186 | $8,088.52 | 53,784 | |
| Raykov Rosty | FENC | Director | Feb 5 '25 | Sell | $6.66 | 10,000 | $66,600.00 | 61,156 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
Breakeven Is Near for Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
GuruFocus.com
a month ago
Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Fennec Pharmaceuticals Inc Earnings Call
MT Newswires
a month ago
Wedbush Reviews Fennec Pharmaceuticals' Q4
Simply Wall St.
a month ago
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain
MT Newswires
a month ago
Fennec Pharmaceuticals Q4 Loss Narrows
GlobeNewswire
a month ago
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.